Quantum-Si (NASDAQ: QSI) reported second-quarter 2026 earnings per share (EPS) of $(0.11), beating the analyst consensus estimate of $(0.12) by 8.33 percent. The quarterly loss represented a 31.25 percent improvement over the $(0.16) per share loss recorded in the same period last year.

Revenue for the quarter came in at $344,000, surpassing the consensus estimate of $302,000 by 13.91 percent. Despite beating estimates, this figure reflects a significant contraction from $591,000 in Q2 2025, a decline of 41.79 percent. The revenue drop aligns with limited near-term capital purchasing for the current Platinum platform and strategic positioning for the upcoming Proteus system transition.

In a major strategic update, management announced that the launch of the Proteus instrument is delayed to Q2 2027. This decision allows for an additional integrated instrument design cycle to reduce manufacturing risk and improve product readiness. CEO Jeff Hawkins stated the delay was internally driven by assessments of performance repeatability and manufacturing yields, rather than new customer feedback.

Financial Performance

To align expenses with the revised timeline, Quantum-Si implemented cost-saving measures including a 20% reduction in total headcount. These actions are expected to generate approximately $12 million in annualized operating expense savings once fully implemented. The company emphasized it preserved investment in critical work streams required for the Proteus launch.

Gross margin improved to 50% in Q2 2026, up from 41% in the first half of the year. GAAP operating expenses decreased to $25.8 million from $30.5 million in Q2 2025. Adjusted operating expenses were $22.6 million, down from $23.8 million in the prior-year quarter.

The net loss narrowed to $23.5 million from $28.8 million in Q2 2025. Adjusted EBITDA improved slightly to negative $21.2 million from negative $22.2 million in the prior-year period. Dividend and interest income declined to $1.7 million from $2.3 million, reflecting changes in invested balances and the rate environment.

What the Numbers Show

The divergence between the narrowing net loss and the widening revenue gap highlights the effectiveness of the company's expense discipline. While revenue contracted by nearly 42%, the net loss reduced by approximately 18%, indicating that operating leverage is being achieved through strict cost control rather than top-line growth. Furthermore, with cash and investments standing at $169.9 million as of June 30, 2026, and projected cash usage capped at $93 million for FY26, the company maintains sufficient capital to fund operations into Q4 2028.

Strategic Outlook

Management reiterated full-year 2026 guidance of approximately $1 million in revenue and adjusted operating expenses of $98 million or less. The company expects to launch Proteus with detection capability for either 19 or 20 amino acids, an improvement over the previous target of 18. Quantum-Si also highlighted opportunities in non-human proteomics, citing an estimated $4 billion annual market potential in pathogen and agricultural research sectors.

Quantum-Si Incorporated has granted 134,141 restricted stock units (RSUs) to new employees as an inducement material to their employment with the company. The grants were made under the Company's previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, as amended, and in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2023 Inducement Plan is used exclusively for equity awards to individuals who were not previously employees of Quantum-Si, or following a bona fide period of non-employment. These awards serve as an inducement for such individuals to enter into employment with Quantum-Si pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

The RSUs will vest 25% on June 20, 2027. The remainder will vest in 12 equal quarterly installments thereafter, subject to the employee's continued employment with Quantum-Si on the applicable vesting dates. The RSUs are subject to the terms and conditions of the 2023 Inducement Plan and a RSU agreement covering the grant.

Grant Details

Quantum-Si is a proteomics company focused on redefining protein analysis through single-molecule protein sequencing.